GSK1059615

 Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw

Biological Activity

Description	GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively. Phase 1.
Targets	PI3Kα	PI3Kβ	PI3Kδ	PI3Kγ	mTOR
IC50	0.4 nM	0.6 nM	2 nM	5 nM	12 nM [1]
In vitro	The pyridinylquinoline derivative GSK1059615 is a novel, ATP-competitive, and reversible inhibitor of the class I family of PI3Ks. GSK1059615 inhibits PI3K signaling, induces G1 arrest and apoptosis, especially in breast tumor cells. [2] Data summarized in another review also shows that GSK1059615 inhibits PI3Kα, β, γ and δ, with Ki of 0.42 nM, 0.6 nM, 0.47 nM and 1.7 nM, respectively. [3] Another report shows that GSK1059615 inhibits PI3Kα with IC50 of 2 nM. In T47D and BT474 cancer cells, GSK1059615 inhibits the phosphorylation of Akt at S473, with IC50 of 40 nM. [4]
In vivo	In xenograft mice models of BT474 or HCC1954 breast cancer cells, GSK1059615 (25 mg/kg) effectively inhibits tumor growth. [3]
Features	A novel, ATP-competitive, and reversible inhibitor of both PI3Kα, β, δ, and γ, and mTOR.

Protocol(Only for Reference)

Kinase Assay: ^[4]

HTRF In vitro Profiling Assays for PI3K Inhibition

The measurement of the GSK1059615-dependent inhibition of the PI3Ks is accessed using a HTRF based PI3K profiling assay kit. 400 pM enzyme is used in PI3Kα and δ assays, 200 pM in PI3Kβ assays, and 1 nM in PI3Kγ assay. In addition, the PI3Kα, β, and δ assays are run with 150 mM NaCl and 100 μM ATP, while the PI3Kγ assay is run with no NaCl and 15 μM ATP. All reactions are run at 10 μM PIP2. GSK1059615 is serially diluted (3-fold in DMSO), and 50 nL is transferred to a 384-well low-volume assay plate. PI3K Reaction Buffer is prepared by diluting the stock 1:4 with de-ionized water. Freshly prepared DTT is added at a final concentration of 5 mM on the day of use. Enzyme addition and GSK1059615 pre-incubation are initiated by the addition of 2.5 µL of PI3K in reaction buffer. Plates are incubated at room temperature for 15 min. Reactions are initiated by addition of 2.5 µL of 2× substrate solution (PIP2 and ATP in 1× reaction buffer). Plates are incubated at room temperature for one hour. Reactions are quenched by the addition of 2.5 µL of stop solution. The quenched reactions are then processed to detect product formation by adding 2.5 µL of Detection Solution. Following a 1-hour incubation in the dark, the HTRF signal is measured on the Envision plate reader set for 330nm excitation and dual emission detection at 620nm (Eu) and 665nm (APC). The IC50 value is then obtained.

Cell Assay: ^[4]

Cell lines	T47D and BT474 cells
Concentrations	0–1 μM, serially diluted (3-fold) in DMSO
Incubation Time	30 min
Method	Cells are plate at a density of 1 × 104 cells per well in clear flat-bottomed 96-well plates and incubated overnight. Then, GSK1059615 is added and the plates are incubated for 30 min. At the end of incubation, media is aspirated from the plates, and the plate is wash once with cold PBS. 80 μL MSD Lysis buffer is added into each well and the plates are incubated on a shaker at 4 °C for at least 30 min. For Akt duplex assay, plates are washed with 200 μL/well wash buffer for 4 times and tapped on paper towel to blot. Then, 60 μL lysates is added to each well and the plates are incubated on shaker at room temperature for 1 hour. After another 4 times washing, antibody is added (25 μL per well) and the plates are incubated on shaker for 1 hour and washed again. Finally, Read Buffer is added (150 μL per well) and the plates are read immediately. IC50 values are then obtained.

Animal Study: ^[3]

Animal Models	Xenograft mice models of BT474 or HCC1954 cells
Dosages	25 mg/kg
Administration	Oral gavage

1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number	Recruitment	Conditions	Sponsor /Collaborators	Start Date	Phases
NCT00695448	Terminated	Solid Tumours|Metastatic Breast Cancer|Solid Tumor Cancer|Lymphoma|Endometrial Cancer	GlaxoSmithKline	2008-06	Phase 1

Chemical Information

Download GSK1059615 SDF

Chemical Name	(Z)-5-((4-(pyridin-4-yl)quinolin-6-yl)methylene)thiazolidine-2,4-dione

Customer Reviews (4)

Click to enlarge	Rating
	Source	Antonino Maria Spartà from University of Bologna.GSK1059615 purchased from Selleck
	Method	Western Blot/MTT
	Cell Lines	Molt-4 leukemia cell
	Concentrations	2.7 μM
	Incubation Time	48 h
	Results	PI3K Inhibitor GSK-1059615 was able to induce Molt-4 leukemia cell death after 48 h treatment with an IC50 of around 2.7 mM. It was also able to induce apoptosis, but to a very limited extent as shown by Caspase 7 western blot.

Product Citations (2)

• 
  

  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. [Misale S, et al. Nature 2012;486(7404):532-6]

  
  PubMed: 22722830


• 
  

  Metrics other than potency reveal systematic variation in responses to cancer drugs [Fallahi-Sichani M, et al. Nat Chem Biol 2013;9(11):708-14]

  
  PubMed: 24013279